| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.75(B) |
| Last
Volume: |
679,143 |
Avg
Vol: |
1,075,670 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
7,161 |
9,748 |
12,417 |
12,417 |
| Total Sell Value |
$114,090 |
$152,803 |
$201,886 |
$201,886 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
3 |
4 |
4 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bonello William |
President, Informatics |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,824 |
12,060 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
34,945 |
2,316,073 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,571 |
333,402 |
|
- |
|
| Pedulla Denise E |
General Counsel |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,912 |
43,988 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,330 |
24,980 |
|
- |
|
| Mckenzie Kathryn B |
Chief Financial Officer |
• – – |
2020-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(168) |
2,105 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2020-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(810) |
144,830 |
|
- |
|
| Bonello William |
President, Informatics |
• – – |
2020-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(499) |
6,236 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,353) |
2,281,128 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2020-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(212) |
22,650 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2019-12-30 |
4 |
OE |
$4.78 |
$478,000 |
I/I |
100,000 |
1,625,000 |
|
- |
|
| Mckenzie Kathryn B |
Chief Accounting Officer |
• – – |
2019-12-10 |
4 |
S |
$26.37 |
$210,960 |
D/D |
(8,000) |
2,273 |
|
- |
|
| Mckenzie Kathryn B |
Chief Accounting Officer |
• – – |
2019-12-10 |
4 |
OE |
$8.03 |
$64,240 |
D/D |
8,000 |
10,273 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2019-11-21 |
4 |
GD |
$24.53 |
$1,226,500 |
D/D |
50,000 |
195,234 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2019-11-21 |
4 |
S |
$24.27 |
$562,142 |
I/I |
(23,162) |
1,525,000 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2019-11-20 |
4 |
S |
$24.35 |
$3,118,456 |
I/I |
(128,068) |
1,548,162 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2019-11-15 |
4 |
S |
$23.45 |
$160,234 |
D/D |
(6,833) |
22,862 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2019-11-15 |
4 |
OE |
$7.52 |
$51,469 |
D/D |
6,833 |
29,695 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2019-11-12 |
4 |
S |
$23.15 |
$450,129 |
D/D |
(19,444) |
325,831 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2019-11-12 |
4 |
OE |
$7.15 |
$317,775 |
D/D |
44,444 |
345,275 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2019-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(205,635) |
2,277,391 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2019-11-08 |
4 |
OE |
$7.15 |
$3,378,568 |
D/D |
472,527 |
2,483,026 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2019-11-07 |
4 |
S |
$22.80 |
$91,200 |
D/D |
(4,000) |
300,831 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2019-11-06 |
4 |
S |
$22.82 |
$1,176,508 |
D/D |
(51,556) |
304,831 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2019-11-06 |
4 |
OE |
$7.15 |
$397,225 |
D/D |
55,556 |
356,387 |
|
- |
|
544 Records found
|
|
Page 9 of 22 |
|
|
0.29 (2.07%) 
